reports
EXL Announces Share Repurchase of 1,551,970 Shares
EXL Announces Share Repurchase of 1,551,970 Shares NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- [NASDAQ: EXLS], a global data and AI company, announced that on December 15, 2025 it repurchased 1,551,970 shares of the Company’s common stock from Orogen Echo LLC (“Orogen”), an affiliate of The Orogen Group LLC, for an aggregate purchase price of $63,373,143, based on a purchase price per share of $40.834, which is the volume weighted average price over the 5 days prior to settlement. The shares were privately repurchased from Orogen under a Stock Purchase Agreement dated as of December 15, ...
Hooker Furnishings Completes Sale of Pulaski Furniture and Samuel Lawr...
Hooker Furnishings Completes Sale of Pulaski Furniture and Samuel Lawrence Furniture for Approximately $6.1 Million MARTINSVILLE, Va., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Hooker Furnishings Corporation (NASDAQ-GS: HOFT) (“Hooker” or the “Company”), a global leader in home furnishings, today announced it has completed the sale of the Pulaski Furniture and Samuel Lawrence Furniture casegoods brands to Magnussen Home Furnishings, Inc. for approximately $6.1 million, subject to certain final customary post-closing adjustments. “Completing this transaction marks a significant milestone in our j...
Kymera Therapeutics Announces Closing of Upsized $602 Million Public O...
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the closing of its upsized underwritten public offering of $602.0 million of shares of its common stock. Kymera sold and issued 8,050,000 shares of its common stock, which includes 1,050,000 shares so...
EXL completes migration of LifePRO Digital Suite® platforms to AWS
EXL completes migration of LifePRO Digital Suite® platforms to AWS NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- [Nasdaq: EXLS], a global data and AI company, announced the successful migration of its platforms to Amazon Web Services (AWS). This milestone underscores EXL’s commitment to modernizing the life and annuity industry while deepening its collaboration with AWS. The migration to AWS provides EXL clients with a secure, scalable and resilient infrastructure that supports faster innovation and greater flexibility. By leveraging Amazon Bedrock and Kendra, EXL delivers innovative sol...
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-6...
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported by mid-2027 and BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degra...
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public O...
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $602.0 million of shares of its common stock. Kymera is selling 7,000,000 shares of common stock in the offering, which are being sold at a public offering price of $86.00 per share. In addition, Kymera has granted the un...
Kymera Therapeutics Announces Proposed Public Offering
Kymera Therapeutics Announces Proposed Public Offering WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares of common stock to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional...
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b C...
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) patients KT-621 achieved strong reductions in disease-relevant Type 2 biomarkers in blood, including TARC (median reduction of 74% in patients with baseline TARC...
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermati...
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BroADen Phase 1b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, December 8,...
ExlService Holdings Inc: 1 director
A director at ExlService Holdings Inc sold 11,774 shares at 39.990USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Seneca Foods Corp: 1 director
A director at Seneca Foods Corp sold 2,634 shares at 119.380USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Hooker Furnishings Announces Sale of Two Brands within Home Meridian S...
Hooker Furnishings Announces Sale of Two Brands within Home Meridian Segment MARTINSVILLE, Va., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Hooker Furnishings Corporation (NASDAQ-GS: HOFT) (“Hooker” or the “Company”), a global leader in home furnishings, today announced it has entered into a definitive agreement to sell its Pulaski Furniture and Samuel Lawrence Furniture casegoods brands to Magnussen Home Furnishings, Inc. (“Magnussen”). Pursuant to the terms of the asset purchase agreement, an estimated purchase price will be determined and paid at closing based upon the net book value of the asse...
Data and AI Leader EXL to host ‘IdeaTank’ innovation event at the Nasd...
Data and AI Leader EXL to host ‘IdeaTank’ innovation event at the Nasdaq MarketSite More than 11,000 pitch ideas submitted from EXL employees globally Shark Tank’s Robert Herjavec to join EXL IdeaTank event NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- [NASDAQ: EXLS], a global data and AI company, announced that it will hold its second annual IdeaTank event at the Nasdaq MarketSite on December 8, 2025. A celebration of EXL’s innovation-at-speed culture and AI-native workforce, the event features new data and AI pitch ideas submitted from EXL’s global employee base. Winning ideas receive ...
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b...
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen Phase 1b AD trial with data to be reported in December 2025 WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines f...
Kymera Therapeutics to Participate in Upcoming December Investor Confe...
Kymera Therapeutics to Participate in Upcoming December Investor Conferences WATERTOWN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: Piper Sandler 37th Annual Healthcare Conference in New York, NY on December 2 at 2:30 p.m. ET;Citi 2025 Global Healthcare Conference in Miami, FL on December 3 at 11:15 a.m. ET; andEvercore 8th Annual ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
SHOO STEVEN MADDEN LTD.
NTRA NATERA
MMS MAXIMUS INC.
ISRG INTUITIVE SURGICAL INC.
HOO HERBALIFE NUTRITION LTD.
HIG HARTFORD FINANCIAL SERVICES GROUP INC.
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
BIIB BIOGEN INC.
ADMA ADMA BIOLOGICS INC
D4V G. WILLI-FOOD INTERNATIONAL LTD.
LZB LAZBOY INCORPORATED
HOFT HOOKER FURNITURE CORP.
TNDM TANDEM DIABETES CARE
RCUS ARCUS BIOSCIENCES
CSTL CASTLE BIOSCIENCES
TXG 10X GENOMICS INC CLASS A
NRIX NURIX THERAPEUTICS
ADPT ADAPTIVE BIOTECHNOLOGIES
TYRA TYRA BIOSCIENCES INC
GFR GREENFIRE RESOURCES LTD
SOLV_w SOLVENTUM CORPORATION
PACS PACS GROUP INC
NUTX NUTEX HEALTH INC
BBNX BETA BIONICS
KLRS KALARIS THERAPEUTICS INC
CCHH CCH HOLDINGS LTD
FBRX FORTE BIOSCIENCES INC
EXL named a Leader in Everest Group’s 2025 Clinical and Care Managemen...
EXL named a Leader in Everest Group’s 2025 Clinical and Care Management Operations PEAK Matrix® Assessment NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- [NASDAQ: EXLS], a global data and AI company, announced that it has been named a Leader in Everest Group’s Clinical and Care Management (CCM) Operations PEAK Matrix® Assessment 2025 report. evaluates 20 leading CCM operations providers through its RFI process, client reference checks, and ongoing market analysis. EXL is cited for its embedded data and AI capabilities, flexible engagement model that supports all CCM subprocesses and abili...
EXL named a Leader in Everest Group Property and Casualty (P&C) Insura...
EXL named a Leader in Everest Group Property and Casualty (P&C) Insurance BPS PEAK Matrix® Assessment 2025 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- [NASDAQ: EXLS], a global data and AI company, announced that it has been named a Leader in Everest Group’s Property and Casualty (P&C) Insurance BPS PEAK Matrix® Assessment 2025. Each year, Everest Group presents detailed assessments of P&C business process services (BPS) insurance providers. This year’s report includes 25 companies that are evaluated based on their vision, capabilities and market impact. Researchers determine an organi...
Seneca Foods Reports Sales and Earnings for the Quarter and Six Months...
Seneca Foods Reports Sales and Earnings for the Quarter and Six Months Ended September 27, 2025 FAIRPORT, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Seneca Foods Corporation (NASDAQ: SENEA, SENEB) today announced financial results for the second quarter and six months ended September 27, 2025. Executive Summary (vs. year-ago, year-to-date results): Net sales for the six months ended September 27, 2025 totaled $757.5 million compared to $730.2 million for the six months ended September 28, 2024. The year-over-year increase of $27.3 million was driven by higher sales volumes and the impact o...
EXL named a Leader in 2025 ISG Provider Lens® Generative AI Services G...
EXL named a Leader in 2025 ISG Provider Lens® Generative AI Services Global Report NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- [NASDAQ: EXLS], a global data and AI company, announced that it has been named a Leader in the ISG Provider Lens® Generative AI (GenAI) Services – Large and Midsize Global 2025 report. in two categories: Strategy and Consulting and Development and Deployment Services. EXL was named a Leader in both Midsize categories for the second consecutive year, recognized for its ability to help enterprise leaders make informed buying decisions and maximize their technolog...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.